Moderna’s individualized mRNA-4157 vaccine was added to Keytruda or compared to Keytruda alone. Over a two-year period, the combination of the mRNA vaccine with the checkpoint inhibitor reduced the risk of recurrence or death by 44% compared with Keytruda alone. There was also a lower recurren...